Hydrochloric Acid

Hydrochloric Acid

SCHEMBL1360048

CNCC(=O)OC.[Cl-].[H+]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL363759 0.94
Hydrochloric Acid SCHEMBL380580 0.92
Ammonia Solution, Strong SCHEMBL1111047 0.92
Acetic Acid SCHEMBL28554233 0.86 GAA (0.48)
SCHEMBL5349106 0.77 RECQL (0.61)
Butyric Acid SCHEMBL28166159 0.77 FFAR3 (0.54)
SCHEMBL124341 0.77 ALDH1A1 (0.41)
SCHEMBL28528228 0.76 GAA (0.48)
SCHEMBL17837031 0.76
SCHEMBL19380638 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 EP disclosed
US-20240228469-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-07-11 US disclosed
US-20240217951-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-07-04 US disclosed
CN-113453762-B Pentacyclic heterocyclic compounds 卫材R&D管理有限公司 2024-06-07 CN disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 US disclosed
US-11802107-B2 Compounds and methods of use SIGNUM BIOSCIENCES, INC. (US) 2023-10-31 US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 US disclosed
WO-2023148501-A1 HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS C4X DISCOVERY LIMITED (GB) 2023-08-10 WO disclosed
US-20230174467-A1 COMPOUNDS AND METHODS OF USE SIGNUM BIOSCIENCES, INC. (US) 2023-06-08 US disclosed
CN-110475474-A Compound and application method SIGNUM BIOSCIENCES INC 2019-11-19 CN disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 US disclosed
US-10239889-B1 Pentacyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-03-26 US disclosed
US-20190071452-A1 PENTACYCLIC COMPOUND EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-03-07 US disclosed
WO-2018132759-A1 COMPOUNDS AND METHODS USE SIGNUM BIOSCIENCES, INC. (US) 2018-07-19 WO disclosed
US-20170056419-A1 Methods and Compositions for Inhibiting Clostridium difficile Spore Germination and Outgrowth TUFTS UNIVERSITY 2017-03-02 US disclosed
US-9340569-B2 Methods and compositions for inhibiting clostridium difficile spore germination and outgrowth TUFTS UNIVERSITY (US) 2016-05-17 US disclosed
US-20110280847-A1 METHODS AND COMPOSITIONS FOR INHIBITING CLOSTRIDIUM DIFFICILE SPORE GERMINATION AND OUTGROWTH TUFTS UNIVERSITY (US) 2011-11-17 US disclosed
EP-2367839-A2 METHODS AND COMPOSITIONS FOR INHIBITING CLOSTRIDIUM DIFFICILE SPORE GERMINATION AND OUTGROWTH Tufts University (US) 2011-09-28 EP disclosed
WO-2010062369-A2 METHODS AND COMPOSITIONS FOR INHIBITING CLOSTRIDIUM DIFFICILE SPORE GERMINATION AND OUTGROWTH TUFTS UNIVERSITY (US) 2010-06-03 WO disclosed